tbuckley/cabot-search huggingface dataset:
PTU-277 Coding errors lead to high financial penalties in surgical readmissions:
Authors: MD Gill, L Darwich, J Fletcher, I Ashraf, N Mackenzie
Journal: Gut (2015)

<h3>Introduction</h3> Readmission rates in general surgery are now used as an indicator of outcome of hospital care. Financial penalties for high levels of readmissions were introduced in 2011. Aims of this study were to assess the accuracy of general surgical readmission and cost implications of erroneous coding. <h3>Method</h3> 174 patients were readmitted over a four month period (April – June 2014). Electronic patient records were reviewed for both the primary admission and readmission. <h3>Results</h3> During this time frame, the trust was fined £85,320 in penalties, of which £36,851 could have been avoided if coding errors were excluded. <h3>Conclusion</h3> Robust systems need to be instituted to avoid excessive charges as a result of inaccurate coding. Collaboration with clinical commissioning groups (CCGs) to reduce the penalty for readmissions with an unrelated primary complaint should be carried out. <h3>Disclosure of interest</h3> None Declared.
Summer
Authors: M. Therese Southgate
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SP0103 Innovative Approaches to Managing Clinically Suspect Arthralgia
Authors: A. van der Helm-Van Mil
Journal: Annals of the Rheumatic Diseases (2015)

The development of Rheumatoid Arthritis (RA) consists of different phases, including the phase of arthralgia without clinically apparent arthritis. In contrast to the other phases that have been studied extensively already, the preclinical phase of symptoms without clinically apparent arthritis is studied scarcely. The symptoms that are specific for a preclinical phase of RA are not yet characterized, which hampers the conduct of intervention trials in patient with symptoms of RA but no clinically apparent arthritis. The chronicity of RA is currently considered an unmet meet and in the nearby feature several trials will evaluate whether intervention in the preclinical symptomatic phase of RA is effective in preventing "chronification" of arthritis. This indicates the need to better characterise the symptoms that are specific for a preclinical phase of RA. The clinical expertise is a valuable tool to delineate a subgroup of arthralgia patients with an increased risk on RA. Here I will present two patients with clinically suspect arthralgia and show their disease course. In addition, the ongoing work of an EULAR taskforce that aims to develop criteria for clinically suspect arthralgia (CSA) based on methodology that uses the aggregated expert opinion as external standard will be briefly presented. <h3>Disclosure of Interest</h3> None declared
Laparoscopy and Percutaneous Techniques
Authors: S Adamsen
Journal: Endoscopy (2003)

Laparoscopic techniques are continuing to be developed and refined. While laparoscopic cholecystectomy for gallstone disease has now been practiced for 15 years and is well established and documented, with long-term results available for laparoscopic antireflux surgery, data regarding laparoscopic procedures for common bile duct stones, colon surgery, and other gastrointestinal procedures are still scarce, and the numbers of randomized studies are very limited. The largest number of presentations this year was on antireflux surgery.
111In-Pentetreotide Imaging in Diffuse Idiopathic Neuroendocrine Hyperplasia of the Lung
Authors: Manohar Kuruva, Hemendra R. Shah, Andrew L. Dunn, James E. McDonald
Journal: Clinical Nuclear Medicine (2015)

Diffuse idiopathic endocrine neoplasia of the lung (DIPNECH) is a rare disease characterized by proliferation of neuroendocrine cells in the bronchial wall. Less than 20 cases of DIPNECH have been reported in imaging literature. We present here a case of histopathologically diagnosed DIPNECH with diffusely increased In-octreotide uptake in both lungs.
Pilot Prospective Evaluation of <sup>18</sup>F-Alfatide II for Detection of Skeletal Metastases
Authors: Baoming Mi, Chunjing Yu, Donghui Pan, Min Yang, Weixing Wan, Gang Niu, Xiaoyuan Chen
Journal: Theranostics (2015)

This pilot prospective evaluation study is to verify the efficiency of 18 F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to 18 F-FDG PET.Thirty recruited patients underwent 18 F-FDG and 18 F-alfatide II PET/CT successively within days.The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow.Visual analysis and quantification of SUV max were performed to compare the detection sensitivity of 18 F-Alfatide II and 18 F-FDG PET.Eleven patients were found to have a total of 126 bone metastasis lesions. 18F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than 18 F-FDG PET (77%).Especially, 18 F-Alfatide II PET showed superiority to 18 F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%).In conclusion, 18 F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions.The sensitivity of 18 F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of 18 F-FDG PET/CT.This pilot clinical study warrants the further application of 18 F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.
Genetic Coding Variant in GPR65 Alters Lysosomal pH and Links Lysosomal Dysfunction with Colitis Risk
Authors: Kara G. Lassen, Craig I. McKenzie, Muriel Mari, Tatsuro Murano, Jakob Begun, Leigh A. Baxt, Gautam Goel, Eduardo J. Villablanca, Szu-Yu Kuo, Hailiang Huang, Laurence Macia, Atul K. Bhan, Marcel Batten, Mark J. Daly, Fulvio Reggiori, Charles R. Mackay, Ramnik J. Xavier
Journal: Immunity (2016)
The Ehlers–Danlos Syndrome
Authors: Michael S. Bruno, P. Narasimhan
Journal: New England Journal of Medicine (1961)

OF the various heritable disorders of connective tissue the Ehlers–Danlos syndrome is the oldest, having been first described by Job van Meekeren1 in 1682. In spite of the interest generated by the observations of Kopp,2 du Mesnil,3 Williams,4 Unna,5 Tschernogobow,6 Ehlers7 and finally Danlos,8 who underscored the various characteristics of this condition as it is known today, the world literature contained documented reports of less than 100 cases by 1956, when McKusick9 compiled his monograph. His total experience with the Ehlers–Danlos syndrome at that time included 8 kinships, subsequently increased to 11 kinships by 1960, when the second edition of . . .
Mixed Gonadal Dysgenesis Associated with Unilateral Cavernosal Fibrosis and Presenting as a Cystic Lower Abdominal Mass
Authors: Hartmut E.H. Wegner, Rüdiger Klän, Rolf-Dieter Wegner, Helmut H. Knispel, Alejandra Ferszt, Klaus-Peter Dieckmann
Journal: European Urology (1993)
Soundings: A gift for Thanksgiving
Authors: George Dunea
Journal: BMJ (2003)

Passed in November just before Thanksgiving, the US Medicare reform act is so complicated that it is still unclear who should be giving thanks and who should not (bmj.com 29 Nov 2003, News Extra). At first sight it is a victory for the president, who fulfilled his election pledge to provide affordable prescription drugs to people over 65 and who should have enhanced his re-election prospects. Future taxpayers may give no thanks, because the estimated $400bn (£231bn; €328bn) cost over 10 years may well lead to higher taxes. Insurance companies and employers receiving subsidies to continue employees in their plans are momentarily pleased, and so are the drug companies, which may however end up with price controls some day. At present the Republicans can claim credit for passing a bill after six years of debate and wrangling, but there could be a backlash if senior citizens discover they have to pay for something they now get for free.

Many of the bill's provisions do not become effective until 2006, leaving future administrations to pick up the pieces. In 2004 senior citizens will get a 15% discount card for prescription drugs. In 2006 there comes a complicated system in which seniors pay the first $250 in drug costs, then only 25% until they spend $2250 (insurance pays the rest); coverage ceases until $3600 is spent out of pocket, and then the government takes over and pays 95%. People on high incomes (more than $80 000 a year) will pay higher premiums, while those on low incomes (less than $12 000) will have no deductions and pay less than $5 a prescription. There are numerous subsidies, generic drugs will be promoted, and—to the delight of drug companies—the government will not be allowed to negotiate prices.

The bill passed by 220 to 215 in the House of Representatives and by 54 to 44 in the Senate, after much horse trading and arm twisting and crossing of party lines. It has been characterised as a historic achievement; a tour de force; a red-letter day for seniors; a grand political compromise; a deeply flawed bill; a historic sellout; a financial disaster; a giveaway to special interests; and the beginning of the end for the Great Society.
SP0204 Ensuring that Negative Trials Are Published? Do Clinical Trial Registries Have a Role?
Authors: D. Felson
Journal: Annals of the Rheumatic Diseases (2015)

Publication bias, the failure of small negative trials to be published, has been well documented in all fields of medicine, including rheumatic disease. Evaluating a treatment by summarizing data from only published trials creates an inaccurately rosy picture of a treatment9s efficacy and safety especially when trials have been carried out that remain unpublished. Treatments shown to be ineffective have sometimes been painted as effective in published trial data. Web-based clinical trial registries such as clnicaltrials.gov were created to encourage trialists to publish trial protocols and to even report trial results in these registries. Editors of major medical journals have required prerecruitment registration of trial protocols, creating further pressure to register trials. Current evidence suggests that while trials are increasingly being registered, negative trial results are not necessarily reported there, so that publication bias persists. New strategies to enhance the likeihood of detecting the existence of negative trials include changes in requirements for trial registration and the possible availability of trial data through companies and regulatory agencies. <h3>Disclosure of Interest</h3> None declared
Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients
Authors: J J Mann, K M Malone, D A Nielsen, D Goldman, J Erdos, J Gelernter
Journal: American Journal of Psychiatry (1997)

This study was designed to test the hypothesis that serotonin-system-related genes may be correlated with suicide risk.Fifty-one unrelated Caucasian inpatients with major depression, with or without a history of suicidal acts, were genotyped for a biallelic polymorphism at the tryptophan hydroxylase locus.The less common tryptophan hydroxylase U allele occurred with greater frequency in the patients who had attempted suicide. A logistic regression analysis confirmed an association between tryptophan hydroxylase genotype and lifetime history of suicide attempts.Serotonergic-system-related genes may influence the risk of suicide in persons with major depression.
A Method for the Cytologic Detection of Tumor Cells in Whole Blood
Authors: Richard A. Malmgren, John C. Pruitt, Pasco R. Del Vecchio, John F. Potter
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article A Method for the Cytologic Detection of Tumor Cells in Whole Blood Get access Richard A. Malmgren, Richard A. Malmgren Search for other works by this author on: Oxford Academic PubMed Google Scholar John C. Pruitt, John C. Pruitt Search for other works by this author on: Oxford Academic PubMed Google Scholar Pasco R. Del Vecchio, Pasco R. Del Vecchio Search for other works by this author on: Oxford Academic PubMed Google Scholar John F. Potter John F. Potter Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 6, June 1958, Pages 1203–1213, https://doi.org/10.1093/jnci/20.6.1203 Published: 01 June 1958 Article history Received: 18 December 1957 Published: 01 June 1958
Case 37-1962
Authors: Edwin O. Wheeler, Richard B. Cohen
Journal: New England Journal of Medicine (1962)

Presentation of Case First admission. A thirty-nine-year-old seaman entered the hospital because of swelling of the legs and abdomen.Eleven months previously the patient noticed a 20-pound gain over his usual weight of 220 pounds and the development of mild dyspnea after climbing ship ladders. Three months later he had a "heavy cold," with a minor productive cough for a month, but continued his regular activities until six months before entry, when he began to experience increasing exertional dyspnea, with substernal tightness and ankle swelling that disappeared with rest. Three-pillow orthopnea, paroxysmal nocturnal dyspnea, refractory swelling of the legs and . . .
Epidemic cluster of legionnaires’ disease in Paris, June 1998
Authors: B Decludt, L Guillotin, B van Gastel, A Perrocheau, L Capek, M Ledrans, D Carlier, S Jarraud, S Dubrou, M Reyrolle
Journal: Eurosurveillance (1999)

From 29 June to July 1998, four cases of legionnaires disease in British citizens were reported to the Reseau National de Sante Publique (RNSP) by the statutory notification system (declaration obligatoire (DO)) and by theEuropean Surveillance Scheme for
A Comparison of Impaired Function with Morphologic Changes Occurring in Livers of Rats Ingesting &lt;italic&gt;N&lt;/italic&gt;-2-Fluorenyldiacetamide
Authors: Harold P. Morris, Billie P. Wagner, Louise S. Lombard
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article A Comparison of Impaired Function with Morphologic Changes Occurring in Livers of Rats Ingesting N-2-Fluorenyldiacetamide Get access Harold P. Morris, Harold P. Morris National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Billie P. Wagner, Billie P. Wagner National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Louise S. Lombard Louise S. Lombard National Cancer Institute,4Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 1, January 1958, Pages 1–35, https://doi.org/10.1093/jnci/20.1.1 Published: 01 January 1958 Article history Received: 11 June 1957 Published: 01 January 1958
PTU-211 Novel techniques in the treatment of cryptoglandular fistula in ano: a systematic review
Authors: SK Narang, K Keogh, N Alam, S Pathak, I Daniels, N Smart
Journal: Gut (2015)

<h3>Introduction</h3> Fistula in ano represents a complex disease process that can be particularly challenging to treat. Several newer techniques have been developed with the intention of achieving high success rates and minimising damage to the anal sphincter complex. The aim of this systematic review was to review the published literature for novel treatment strategies and assess its effectiveness. <h3>Method</h3> A systematic review of all English language literature relevant to novel treatment strategies for cryptoglandular fistula in ano, published between 1 January 2007 and 31 Dec 2014 was carried out using MEDLINE, EMBASE and the Cochrane Library of Systematic Reviews/Controlled Trials for relevant literature. Relevant articles were identified, quality assessed using the MINORS criteria and the data were extracted by two researchers independently. The identified novel techniques were assessed with regards to the surgical procedure, fistula healing rate, length of follow up and complication rates. <h3>Results</h3> A total of 70 potential articles were identified from the literature search. Using the predefined inclusion and exclusion criteria, 21 articles were included for the final analysis, data extraction and data synthesis. Apart from two RCT, all were retrospective or prospective case series. The identified studies reported the use of novel biomaterials (adipose derived stem cells, platelet rich plasma, Human acellular dermal matrix (ADM), Permacol™ solid implant/suspension, Acellular Dermal Matrix (ADM), Acellular Extracellular Matrix (AEM), Energy devices (Fistula laser closure-FiLaC), new types of seton sutures (Comfort Drain and self-locking cable tie), Hybrid techniques (BioLIFT, LIFT-Plug and Permacol injection-advancement flap), OTSC<sup>TM</sup>Proctology clip system and Video assisted anal fistula treatment (VAAFT). The success rates of the various techniques ranged from 37.3% to 100% over a follow up period ranging from 4–81 months without any major disturbance to continence. <h3>Conclusion</h3> This systematic review has demonstrated that there have been some pioneering technological advances to treat complex cryptoglandular fistula in ano however most of these are in an early stage of evolution. Due to the significant variation in the methodology, study design, outcome reporting of the included studies, it is not possible to meaningfully compare and contrast the described novel techniques. As with most new procedures, the early promising and enthusiastic results are often difficult to reproduce. Longer follow up data is not currently available. <h3>Disclosure of interest</h3> None Declared.
Abstract 100: Feasibility of Selective Brain Cooling during Cardiac Arrest: A Novel Nasopharyngeal Approach
Authors: Manuel C Boller, Joshua Lampe, Lance B Becker
Journal: Circulation (2007)

Introduction: In patients with cardiac arrest, selective brain cooling may improve neurological outcome, especially if applied prior to reperfusion. Thus it is important to develop practically feasible, non-invasive cooling methods for out-of-hospital use. Purpose: Pilot study to test whether a novel nasopharyngeal cooling device leads to selective brain cooling during cardiac arrest. Methods: Domestic swine (35 kg) were anesthetized and routine respiratory and cardiovascular parameters were monitored and recorded. Temperature data were collected from various sites including the forebrain and rectum. After preparation, the cooling device was activated for a duration of 60 minutes. The device consists of two capped plastic tubes that are advanced through the nostrils so that the tip is located in the nasopharynx. A mixture of oxygen (40 L/min) and perfluorocarbon (0.28 ml/L oxygen) is conducted through the tubes and escapes through small openings in the nasopharyngeal area as perfluorocarbon mist. Rapid ev...
Involvement of Mast Cells in α7 Nicotinic Receptor Agonist Exacerbation of Freund's Complete Adjuvant-Induced Monoarthritis in Mice
Authors: Fernando Lopes, Rabea Graepel, Jose Luis Reyes, Arthur Wang, Björn Petri, Jason J. McDougall, Keith A. Sharkey, Derek M. McKay
Journal: Arthritis & Rheumatology (2015)

Objective Activation of antiinflammatory cholinergic (vagal) pathways can reduce inflammation, and in vitro studies support a pivotal role of α7 nicotinic acetylcholine receptors (α7‐nAChR), macrophages, and T cells in these events. The aim of this study was to assess α7‐nAChR agonists as an antiinflammatory treatment for Freund's complete adjuvant (CFA)–induced monoarthritis. Methods Arthritis was induced by intraarticular injection of CFA unilaterally into the knee joints of mice. Animals were treated with α7‐nAChR agonists (AR‐R17779 or A844606), with or without antagonists (COG133 or methyllycaconitine), and joint inflammation and pain were assessed. Experiments were repeated in c‐Kit W‐sh mast cell–deficient mice, and the effects of an α7‐nAChR agonist on mast cell proliferation, migration, and activation by lipopolysaccharide (LPS) were tested. Results Treatment with α7‐nAChR agonists significantly exacerbated CFA‐induced arthritis and pain, as gauged by all indices of assessment, the specificity of which was confirmed by coadministration of an nAChR antagonist that attenuated the increase in disease severity. Toluidine blue–positive mast cells were increased in the joint capsule of CFA plus AR‐R17779–treated mice, and AR‐R17779 enhanced LPS‐induced TNF proliferation and migration of a human mast cell line. The AR‐R17779–driven increase in severity of CFA‐induced arthritis was significantly reduced in mast cell–deficient mice. Conclusion Using CFA to elicit a local inflammatory response, we found that pharmacologic activation of α7‐nAChR exacerbated joint inflammation and pain, in part via mast cells, which illustrates the organ‐ and disease‐specific nature of regulatory neuroimmune mechanisms. Thus, α7‐nAChR activation may not be uniformly antiinflammatory in all types of inflammatory joint disease.